U.S. FDA approves Pfizer's BEQVEZ™ (fidanacogene elaparvovec-dzkt), a one-time gene therapy for adults with Hemophilia B
|
26 April 2024 |
European Commission approves Pfizer's EMBLAVEO® for patients with multidrug-resistant infections and limited treatment options
|
22 April 2024 |
European Commission approves Pfizer's PREVENAR 20® to help protect infants and children against pneumococcal disease
|
13 March 2024 |
Pfizer announces positive top-line data for full season two efficacy of ABRYSVO® for RSV in older adults
|
29 February 2024 |
European Commission approves Pfizer's VELSIPITY® for patients with moderately to severely Active ulcerative colitis
|
23 February 2024 |
The American Cancer Society and Pfizer announce a $15 million, three-year initiative to bridge the gap in cancer care disparities
|
05 February 2024 |
Pfizer recommends shareholders reject the below-market mini-tender offer by TRC Capital Investment Corporation
|
18 January 2024 |
TIVDAK® supplemental Biologics License Application accepted for Priority Review by FDA for patients with recurrent or metastatic cervical cancer
|
10 January 2024 |
Pfizer declares first-quarter 2024 dividend
|
15 December 2023 |
Pfizer announces topline Phase 2b results of oral GLP-1R agonist, danuglipron, in adults with obesity
|
04 December 2023 |
Pfizer and Astellas' XTANDI® approved by U.S. FDA in earlier prostate cancer treatment setting
|
21 November 2023 |
Pfizer and BioNTech announce positive topline data for mRNA-based combination vaccine program against influenza and COVID-19
|
30 October 2023 |
FDA approves PENBRAYA™, the first and only vaccine for the prevention of the five most common serogroups causing meningococcal disease in adolescents
|
23 October 2023 |
U.S. FDA approves Pfizer's BRAFTOVI® + MEKTOVI® for BRAF V600E-mutant metastatic non-small cell lung cancer
|
12 October 2023 |
Pfizer presents new data at IDWeek 2023 highlighting advances in prevention and treatment of certain respiratory illnesses and other infectious diseases
|
09 October 2023 |
U.S. FDA Approves ABRYSVO™, Pfizer's vaccine for the prevention of respiratory syncytial virus (RSV) in infants through active immunization of pregnant individuals 32-36 weeks of gestational age
|
23 August 2023 |
Pfizer's ELREXFIO™ receives U.S. FDA accelerated approval for relapsed or refractory multiple myeloma
|
14 August 2023 |
Bill & Melinda Gates Foundation, Children's Investment Fund Foundation, Pfizer and Becton, Dickinson & Company expand partnership for greater access to injectable contraceptive for women in low- and lower-middle-income countries
|
04 August 2023 |
Pfizer announces executive leadership to advance oncology research and development strategy
|
27 July 2023 |
Pfizer announces New England Journal of Medicine publication on Group B Streptococcus (GBS) maternal vaccine candidate
|
21 July 2023 |